Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive

NCT06710756 is registered in ClinicalTrials.gov with Perspective Therapeutics as lead sponsor.

NCT NCT06710756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06710756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive
Lead sponsor
Perspective Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 28, 2025
Completion date
May 28, 2032
Enrollment
112 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, mesothelioma, ovarian cancer, pancreatic ductal adenocarcinoma, sarcoma